[血液透析患者丙型肝炎的流行、诊断及治疗现状]
[Current status of the prevalence, diagnosis, and treatment of hepatitis C in patients undergoing hemodialysis].
作者信息
Yang G L, Lei X Z
机构信息
Center for Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610000, China.
出版信息
Zhonghua Gan Zang Bing Za Zhi. 2017 Mar 20;25(3):233-236. doi: 10.3760/cma.j.issn.1007-3418.2017.03.016.
Patients undergoing hemodialysis have a higher rate of hepatitis C virus infection than the general population, and due to various factors including hemodialysis and immunosuppression, it is difficult to make a diagnosis. The appearance of direct-acting antiviral agents greatly promotes the treatment of hepatitis C, but there are still no adequate data on their effect and safety in patients undergoing hemodialysis. This article discusses the prevalence, diagnosis, and treatment of hepatitis C in patients undergoing hemodialysis.
接受血液透析的患者丙型肝炎病毒感染率高于普通人群，并且由于包括血液透析和免疫抑制在内的各种因素，很难做出诊断。直接抗病毒药物的出现极大地推动了丙型肝炎的治疗，但关于其在接受血液透析患者中的疗效和安全性仍缺乏充分数据。本文讨论了接受血液透析患者丙型肝炎的患病率、诊断和治疗。
Zotero 插件